Abstract
The purpose of this work is to analyse two things: firstly, the basis of the Government-Pharmaceutical Industry Stability Pact 2001-2004, which aimed to limit annual growth in public pharmaceutical expenditure, creating a favourable environment for research; secondly, assessing whether the proposed objective of creating stability for the Spanish pharmaceutical industry was achieved. It carries out a thorough statistical analysis of a sample of 45 pharmaceutical laboratories, complemented with a cluster analysis of the main variable strategic principles of the industry, revealing that company behaviour has indeed remained stable during the period in question.
